Clinical Characteristic and Surgical Treatment for the Spinal Tenosynovial Giant Cell Tumors (TGCT): Case Series and Literature Review

被引:0
|
作者
Jialin Li
Shaohui He
Kehan Xu
Jianru Xiao
Jing Chu
机构
[1] Second Military Medical University,Department of orthopedic oncology, Changzheng Hospital
[2] Second Military Medical University,Nursing School
关键词
Tenosynovial giant cell tumors (TGCT); Spine; Surgery; Prognosis; Literature review;
D O I
10.1007/s42399-020-00398-7
中图分类号
学科分类号
摘要
Tenosynovial giant cell tumors are rare neoplasms of the tenosynovial tissue that can be either benign or malignant with locally aggressive characteristics. The morbidity in the axial skeletal system is extremely low, and past reports have been incomplete. Thus, we attempted to identify the clinical characteristics of this rare disease and to provide evidence for the choice of a proper surgery. A retrospective study was designed, and 13 patients from 2009 to 2018 were included in the study. All current published studies were retrieved, and 85 cases were included in the analysis. Clinical data, imaging data, therapeutic strategies, and follow-up results for both benign and malignant tumor types were assessed. TGCT can occur in the entire spine from the cervical region to the sacrum, whereas the appendix and the posterior structures of the vertebrae are more commonly involved (85–100%). The overall local recurrence rate was 17.5% after surgical resection. The Fisher’s exact test demonstrated that the difference in the recurrence rate between lesion gross total resection (LGTR) and lesion subtotal resection (LSTR) surgeries was significant (P = 0.003), whereas the question as to whether the LGTR was completed by en bloc or piecemeal methods was not significant (P = 0.41). The malignant tumor type had a very poor prognosis. The local recurrence of TGCT is not uncommon after an insufficient removal. Therefore, standard therapeutic processes and strict monitoring are the decisive prognostic factors. Additionally, decompression surgery may not be enough to treat this condition. The fundamental goal is to thoroughly remove the lesions, whereas there is no need to pursue an en bloc resection. Lesion gross total resection should be the first therapeutic choice, with the goal of also preserving neural function. For the malignant tumor type, taking the first opportunity for an operation is vitally important, and en bloc resection is recommended, with radiotherapy and target therapy also being helpful.
引用
收藏
页码:1666 / 1675
页数:9
相关论文
共 50 条
  • [1] Surgical treatment of spinal tenosynovial giant cell tumor: Experience from a single center and literature review
    Cao, Shiliang
    Jiang, Liang
    Yang, Shaomin
    Liu, Zhongjun
    Wei, Feng
    Liu, Xiaoguang
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [2] Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches
    Spierenburg, Geert
    van der Heijden, Lizz
    van Langevelde, Kirsten
    Szuhai, Karoly
    Bovee, Judith V. G. M.
    van de Sande, Michiel A. J.
    Gelderblom, Hans
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (04) : 333 - 345
  • [3] Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets
    van Der Heijden, Lizz
    Spierenburg, Geert
    Kendal, Joseph K. K.
    Bernthal, Nicholas M. M.
    van de Sande, Michiel A. J.
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (03) : 478 - 488
  • [4] Treatment Modalities for Refractory-Recurrent Tenosynovial Giant Cell Tumor (TGCT): An Update
    Dania, Vasiliki
    Stavropoulos, Nikolaos A.
    Gavriil, Panayiotis
    Trikoupis, Ioannis
    Koulouvaris, Panagiotis
    Savvidou, Olga D.
    Mavrogenis, Andreas F.
    Papagelopoulos, Panayiotis J.
    MEDICINA-LITHUANIA, 2024, 60 (10):
  • [5] Advances in treatment for tenosynovial giant cell tumors
    Palmerini, Emanuela
    Longhi, Alessandra
    Donati, Davide
    Staals, Eric L.
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (12): : 753 - 757
  • [6] Tenosynovial Giant Cell Tumor of the Retropharynx: A Case Report With Literature Review
    Liu, Guo
    Liu, Feng
    ENT-EAR NOSE & THROAT JOURNAL, 2021, 100 (02) : 112 - 115
  • [7] Outcomes of Surgical Treatment for Localized Tenosynovial Giant-Cell Tumor of the Foot and Ankle: A Case Series
    Ipponi, Edoardo
    Ruinato, Alfio Damiano
    Lombardi, Leonardo
    Cordoni, Martina
    De Franco, Silvia
    D'Arienzo, Antonio
    Andreani, Lorenzo
    ACTA MEDICA LITUANICA, 2023, 30 (02) : 163 - 170
  • [8] Giant spinal nerve sheath tumours ? Surgical challenges: case series and literature review
    Lee, Ming-Te
    Panbehchi, Sasan
    Sinha, Priyank
    Rao, Jagan
    Chiverton, Neil
    Ivanov, Marcel
    BRITISH JOURNAL OF NEUROSURGERY, 2019, 33 (05) : 541 - 549
  • [9] An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors
    Kisielewska, Katarzyna
    Rutkowski, Piotr
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025,
  • [10] Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints
    Mastboom, M. J. L.
    Staals, E. L.
    Verspoor, F. G. M.
    Rueten-Budde, A. J.
    Stacchiotti, S.
    Palmerini, E.
    Schaap, G. R.
    Jutte, P. C.
    Aston, W.
    Leithner, A.
    Dammerer, D.
    Takeuchi, A.
    Thio, Q.
    Niu, X.
    Wunder, J. S.
    van de Sande, M. A. J.
    Fiocco, M.
    Dijkstra, P. D. S.
    Van der Wal, R. J. P.
    Daolio, P. A.
    Picci, P.
    Gronchi, A.
    Ferrari, S.
    Ozger, H.
    Maki, R. G.
    Schreuder, H. W. B.
    Van der Geest, I. C. M.
    Bramer, J. A. M.
    Mastboom, W. J. B.
    Boffano, M.
    Goldenitsch, E.
    Companacci, D.
    Cuomo, P.
    Ferguson, P. C.
    Griffin, A. M.
    Sun, Y.
    Schubert, T.
    Patel, K.
    Aranguren, M. S. J.
    Blancheton, A.
    Gouin, F.
    Duerr, H. R.
    Capellen, C. F.
    Schwab, J.
    Iwata, S.
    Vyrva, O.
    Weschenfelder, W.
    Wang, E. H. M.
    Joo, M. Wook
    Kang, Y. K.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2019, 101 (14): : 1309 - 1318